Bone Marrow Transplant Clinical Trial - IGM Biosciences IGM-2323-001


Open (Study open and enrolling)


CONDITION(S): Non-Hodgkin Lymphoma Follicular Lymphoma DLBCL Mantle Cell Lymphoma Marginal Zone Lymphoma - TRIAL: IGM Biosciences IGM-2323-001 - A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma  

This is a Phase 1 study of IGM-2323 in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This study will consist of a dose-escalation stage and a dose-expansion stage where subjects will be enrolled into indication-specific expansion cohorts. IGM-2323 will be administered intravenously (IV).

Trial Type



Phase 1


Non-Hodgkin Lymphoma Follicular Lymphoma DLBCLMantle Cell Lymphoma Marginal Zone Lymphoma